BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34204116)

  • 1. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models.
    Schmitz RL; Weissbach J; Kleilein J; Bell J; Hüttelmaier S; Viol F; Clauditz T; Grabowski P; Laumen H; Rosendahl J; Michl P; Schrader J; Krug S
    Cells; 2021 Jun; 10(6):. PubMed ID: 34204116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
    Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
    Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
    Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
    PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.
    Fujisawa T; Joshi BH; Puri RK
    J Transl Med; 2011 Apr; 9():37. PubMed ID: 21477288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
    Wanek J; Gaisberger M; Beyreis M; Mayr C; Helm K; Primavesi F; Jäger T; Di Fazio P; Jakab M; Wagner A; Neureiter D; Kiesslich T
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.
    Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
    Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
    Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
    Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
    Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
    BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting histone deacetylases in pancreatic ductal adenocarcinoma.
    Schneider G; Krämer OH; Fritsche P; Schüler S; Schmid RM; Saur D
    J Cell Mol Med; 2010 Jun; 14(6A):1255-63. PubMed ID: 19929947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
    BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
    Minjie S; Defei H; Zhimin H; Weiding W; Yuhua Z
    Tumour Biol; 2015 Nov; 36(11):9015-22. PubMed ID: 26084607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Pancreatic Neuroendocrine Neoplastic Cell Fate by Autophagy-Mediated Death.
    Matrood S; de Prisco N; Wissniowski TT; Wiese D; Jabari S; Griesmann H; Wanzel M; Stiewe T; Neureiter D; Klieser E; Mintziras I; Buchholz M; Bartsch DK; Gennarino VA; Di Fazio P
    Neuroendocrinology; 2021; 111(10):965-985. PubMed ID: 33108790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
    von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
    Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
    Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
    J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.